Biovica International AB (publ) (BIOVIC-B.ST) Research

Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.

Market snapshot

Symbol
BIOVIC-B.ST
Price
$0.42
Day change
+14.79%
Market cap
$77.6M
P/E ratio
-1.17x
52-week range
0.27-0.898
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Alligator Bioscience AB (publ) (ATORX.ST)
  • Biosergen AB (BIOSGN.ST)
  • Iconovo AB (publ) (ICO.ST)
  • Immunovia AB (publ) (IMMNOV.ST)
  • Nanologica AB (publ) (NICA.ST)
  • NextCell Pharma AB (NXTCL.ST)
  • Pila Pharma AB (publ) (PILA.ST)

Open Biovica International AB (publ) (BIOVIC-B.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.